Product Description
Mechanisms of Action: MUC1 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pancreatic Cancer|Adenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PANCRIT®-1 | P3 |
Terminated |
Pancreatic Cancer |
2016-11-01 |
|
PANCRIT-1 (PANcreatic Cancer RadioImmunoTherapy Trial 1) | P3 |
Completed |
Adenocarcinoma|Pancreatic Cancer |
2016-03-14 |